Incidental Mutation 'P0007:Lgi3'
ID |
7587 |
Institutional Source |
Beutler Lab
|
Gene Symbol |
Lgi3
|
Ensembl Gene |
ENSMUSG00000033595 |
Gene Name |
leucine-rich repeat LGI family, member 3 |
Synonyms |
|
MMRRC Submission |
038263-MU
|
Accession Numbers |
|
Essential gene? |
Probably non essential
(E-score: 0.061)
|
Stock # |
P0007 (G1)
|
Quality Score |
|
Status
|
Validated
|
Chromosome |
14 |
Chromosomal Location |
70768125-70775764 bp(+) (GRCm39) |
Type of Mutation |
missense |
DNA Base Change (assembly) |
A to G
at 70774152 bp (GRCm39)
|
Zygosity |
Heterozygous |
Amino Acid Change |
Tyrosine to Cysteine
at position 442
(Y442C)
|
Ref Sequence |
ENSEMBL: ENSMUSP00000046705
(fasta)
|
Gene Model |
predicted gene model for transcript(s):
[ENSMUST00000047331]
[ENSMUST00000226548]
|
AlphaFold |
Q8K406 |
Predicted Effect |
probably damaging
Transcript: ENSMUST00000047331
AA Change: Y442C
PolyPhen 2
Score 0.999 (Sensitivity: 0.14; Specificity: 0.99)
|
SMART Domains |
Protein: ENSMUSP00000046705 Gene: ENSMUSG00000033595 AA Change: Y442C
Domain | Start | End | E-Value | Type |
signal peptide
|
1 |
30 |
N/A |
INTRINSIC |
low complexity region
|
31 |
47 |
N/A |
INTRINSIC |
LRR
|
87 |
110 |
2.63e0 |
SMART |
LRR
|
111 |
134 |
1.07e0 |
SMART |
LRR_TYP
|
135 |
158 |
2.84e-5 |
SMART |
LRRCT
|
170 |
219 |
2.76e-4 |
SMART |
Pfam:EPTP
|
222 |
263 |
7.6e-13 |
PFAM |
Pfam:EPTP
|
268 |
309 |
1.3e-12 |
PFAM |
Pfam:EPTP
|
314 |
360 |
1.1e-14 |
PFAM |
Pfam:EPTP
|
363 |
405 |
2.4e-9 |
PFAM |
Pfam:EPTP
|
410 |
452 |
1.2e-11 |
PFAM |
Pfam:EPTP
|
455 |
496 |
2.2e-12 |
PFAM |
Pfam:EPTP
|
501 |
541 |
2.4e-7 |
PFAM |
|
Predicted Effect |
noncoding transcript
Transcript: ENSMUST00000226376
|
Predicted Effect |
probably benign
Transcript: ENSMUST00000226548
|
Meta Mutation Damage Score |
0.5930 |
Coding Region Coverage |
- 1x: 85.2%
- 3x: 80.2%
- 10x: 65.3%
- 20x: 42.8%
|
Validation Efficiency |
94% (102/109) |
Allele List at MGI |
All alleles(2) : Targeted(2)
|
Other mutations in this stock |
Total: 8 list
Gene | Ref | Var | Chr/Loc | Mutation | Predicted Effect | Zygosity |
Adamts6 |
A |
G |
13: 104,433,999 (GRCm39) |
T143A |
possibly damaging |
Het |
Cfap74 |
T |
A |
4: 155,506,685 (GRCm39) |
S139T |
possibly damaging |
Het |
Fbxo7 |
T |
C |
10: 85,869,157 (GRCm39) |
S204P |
possibly damaging |
Het |
Itga2 |
A |
T |
13: 115,002,735 (GRCm39) |
I585N |
probably damaging |
Het |
Magi1 |
A |
G |
6: 93,722,969 (GRCm39) |
I530T |
probably damaging |
Het |
Med12l |
T |
C |
3: 58,998,816 (GRCm39) |
|
probably benign |
Het |
Nbeal1 |
A |
G |
1: 60,358,847 (GRCm39) |
I1176M |
probably damaging |
Het |
Ostn |
G |
T |
16: 27,143,279 (GRCm39) |
G36* |
probably null |
Het |
|
Other mutations in Lgi3 |
Allele | Source | Chr | Coord | Type | Predicted Effect | PPH Score |
IGL01639:Lgi3
|
APN |
14 |
70,770,825 (GRCm39) |
missense |
probably benign |
0.05 |
IGL02203:Lgi3
|
APN |
14 |
70,771,958 (GRCm39) |
missense |
possibly damaging |
0.68 |
R0114:Lgi3
|
UTSW |
14 |
70,768,469 (GRCm39) |
start gained |
probably benign |
|
R0225:Lgi3
|
UTSW |
14 |
70,770,261 (GRCm39) |
missense |
probably benign |
|
R0242:Lgi3
|
UTSW |
14 |
70,772,255 (GRCm39) |
nonsense |
probably null |
|
R0242:Lgi3
|
UTSW |
14 |
70,772,255 (GRCm39) |
nonsense |
probably null |
|
R0244:Lgi3
|
UTSW |
14 |
70,772,138 (GRCm39) |
missense |
probably benign |
0.30 |
R0396:Lgi3
|
UTSW |
14 |
70,772,280 (GRCm39) |
missense |
probably damaging |
1.00 |
R0479:Lgi3
|
UTSW |
14 |
70,771,992 (GRCm39) |
unclassified |
probably benign |
|
R1652:Lgi3
|
UTSW |
14 |
70,768,656 (GRCm39) |
missense |
probably damaging |
0.99 |
R1840:Lgi3
|
UTSW |
14 |
70,772,216 (GRCm39) |
splice site |
probably null |
|
R1930:Lgi3
|
UTSW |
14 |
70,773,708 (GRCm39) |
missense |
probably damaging |
0.98 |
R1931:Lgi3
|
UTSW |
14 |
70,773,708 (GRCm39) |
missense |
probably damaging |
0.98 |
R2474:Lgi3
|
UTSW |
14 |
70,770,689 (GRCm39) |
critical splice donor site |
probably null |
|
R4672:Lgi3
|
UTSW |
14 |
70,771,897 (GRCm39) |
missense |
possibly damaging |
0.62 |
R5979:Lgi3
|
UTSW |
14 |
70,773,900 (GRCm39) |
missense |
probably damaging |
1.00 |
R6385:Lgi3
|
UTSW |
14 |
70,768,610 (GRCm39) |
missense |
possibly damaging |
0.66 |
R7146:Lgi3
|
UTSW |
14 |
70,770,832 (GRCm39) |
missense |
probably damaging |
1.00 |
R7314:Lgi3
|
UTSW |
14 |
70,769,552 (GRCm39) |
missense |
probably damaging |
1.00 |
R7712:Lgi3
|
UTSW |
14 |
70,768,551 (GRCm39) |
missense |
unknown |
|
R8124:Lgi3
|
UTSW |
14 |
70,772,178 (GRCm39) |
missense |
probably damaging |
1.00 |
R8417:Lgi3
|
UTSW |
14 |
70,772,246 (GRCm39) |
missense |
probably benign |
0.00 |
R8826:Lgi3
|
UTSW |
14 |
70,768,712 (GRCm39) |
critical splice donor site |
probably null |
|
R8881:Lgi3
|
UTSW |
14 |
70,770,282 (GRCm39) |
missense |
probably damaging |
1.00 |
R9186:Lgi3
|
UTSW |
14 |
70,772,193 (GRCm39) |
missense |
probably damaging |
1.00 |
|
Protein Function and Prediction |
LGI3 is a member of the LGI/epitempin family (1). LGI3 has been shown to regulate the internalization of beta-amyloid protein and transferrin (2-4). It is proposed that LGI3 is involved in endocytosis in the brain (2).
Studies downregulating the LGI3 complex (with Flo1) disrupted beta-amyloid precursor protein trafficking to late endosomes and the formation of exosome, indicating a role for LGI3 in intracellular transport via its interaction with the co-factor Flo1 (2). An association with syntaxin 1 at synapses indicates that LGI3 may have a role in the regulation of exocytosis (5). Knockdown of LGI3 resulted in decreased neurite outgrowth; LGI3 overexpression resulted in increased neurite outgrowth (6). In another study, knockdown of LGI3 in 3T3-L1 cells increased the lipid content in adipocytes and adipogenic differentiation markers were upregulated, indicating a negative regulatory role for LGI3 in adipogenesis (1).
|
Expression/Localization |
LGI3 is a secreted protein (1). Semiquantitative PCR determined that, in human tissues, LGI3 is ubiquitously expressed with highest expression in the brain and lung (7). In situ hybridization of adult mouse brain determined that Lgi3 is expressed at high levels in the facial nerve nucleus, while it is expressed at lower levels in other brain regions (8).
|
References |
1. Kim, H. A., Park, W. J., Jeong, H. S., Lee, H. E., Lee, S. H., Kwon, N. S., Baek, K. J., Kim, D. S., and Yun, H. Y. (2012) Leucine-Rich Glioma Inactivated 3 Regulates Adipogenesis through ADAM23. Biochim Biophys Acta. 1821, 914-922.
4. Kimura, N., Ishii, Y., Suzaki, S., Negishi, T., Kyuwa, S., and Yoshikawa, Y. (2007) Abeta Upregulates and Colocalizes with LGI3 in Cultured Rat Astrocytes. Cell Mol Neurobiol. 27, 335-350.
5. Park, W. J., Lee, S. E., Kwon, N. S., Baek, K. J., Kim, D. S., and Yun, H. Y. (2008) Leucine-Rich Glioma Inactivated 3 Associates with Syntaxin 1. Neurosci Lett. 444, 240-244.
6. Park, W. J., Lim, Y. Y., Kwon, N. S., Baek, K. J., Kim, D. S., and Yun, H. Y. (2010) Leucine-Rich Glioma Inactivated 3 Induces Neurite Outgrowth through Akt and Focal Adhesion Kinase. Neurochem Res. 35, 789-796.
7. Gu, W., Wevers, A., Schroder, H., Grzeschik, K. H., Derst, C., Brodtkorb, E., de Vos, R., and Steinlein, O. K. (2002) The LGI1 Gene Involved in Lateral Temporal Lobe Epilepsy Belongs to a New Subfamily of Leucine-Rich Repeat Proteins. FEBS Lett. 519, 71-76.
|
Posted On |
2012-10-05 |
Science Writer |
Anne Murray |